We are live on ! Find out more
MBX

MBX Biosciences
MBX

45 hedge funds and large institutions have $784M invested in MBX Biosciences in 2024 Q3 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

95.24% more ownership

Funds ownership: 0% → 95.24% (+95%)

Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
0.65%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.04%
New
45
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$137M
2
O
OrbiMed
New York
+$87.2M
3
NMC
NEA Management Company
Maryland
+$82.7M
4
DTC
Deep Track Capital
Connecticut
+$69M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$155M +$137M +5,985,347 New
O
2
OrbiMed
New York
$99M +$87.2M +3,812,215 New
NMC
3
NEA Management Company
Maryland
$93.9M +$82.7M +3,614,486 New
DTC
4
Deep Track Capital
Connecticut
$78.4M +$69M +3,018,935 New
Wellington Management Group
5
Wellington Management Group
Massachusetts
$74.3M +$67.2M +2,937,853 New
NA
6
NVP Associates
California
$55.5M +$48.9M +2,136,335 New
RCM
7
RA Capital Management
Massachusetts
$39.3M +$34.6M +1,511,334 New
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$31M +$27.3M +1,192,938 New
EC
9
EcoR1 Capital
California
$30.5M +$26.9M +1,175,809 New
DCM
10
Driehaus Capital Management
Illinois
$25.5M +$22.4M +981,322 New
CAM
11
Cormorant Asset Management
Massachusetts
$18.2M +$16M +700,000 New
TCM
12
TCG Crossover Management
California
$16.9M +$14.9M +650,000 New
WP
13
Woodline Partners
California
$13.5M +$11.9M +519,675 New
Millennium Management
14
Millennium Management
New York
$11.4M +$10.1M +440,411 New
Franklin Resources
15
Franklin Resources
California
$10.6M +$10.3M +450,000 New
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$5.85M +$5.15M +225,000 New
PIM
17
Platinum Investment Management
Australia
$3.9M +$3.43M +150,000 New
Citadel Advisors
18
Citadel Advisors
Florida
$3.52M +$3.1M +135,608 New
Goldman Sachs
19
Goldman Sachs
New York
$1.32M +$1.17M +51,000 New
MS
20
Maven Securities
Jersey
$1.3M +$1.14M +50,000 New
MIM
21
Monashee Investment Management
Massachusetts
$1.3M +$1.14M +50,000 New
SC
22
Stempoint Capital
New York
$1.3M +$1.14M +50,000 New
Vanguard Group
23
Vanguard Group
Pennsylvania
$1.3M +$1.14M +50,000 New
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.2M +$1.06M +46,194 New
TD Asset Management
25
TD Asset Management
Ontario, Canada
$1.07M +$1.02M +44,782 New
1
2

MBX Hedge Fund Activity: Q3 2024 in Review

45 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q3 2024, worth a combined $784M.

Buyers outnumbered sellers: 45 funds opened new MBX positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $137M.

  • 45 institutional investors held MBX Biosciences (MBX) as of Q3 2024, up from 0 in Q2 2024.
  • Funds reported $784M of MBX Biosciences stock for Q3 2024.
  • 45 funds opened new MBX Biosciences positions in Q3 2024 and 0 closed out, a net change of +45 holders.
  • The largest MBX Biosciences buyer in Q3 2024 was Frazier Life Sciences Management, an estimated $137M added.

Based on aggregated 13F filings for Q3 2024.